Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q3 2022 Earnings Presentation
9 slides from Hls Therapeutics's earnings presentation, Nov 10, 2022
Slide 1: Q3 2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q3 2022 Results Conference Call November 10, 2022 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Q3 2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q3 2022 Results Conference Call November 10, 2022 TSX - HLS
Slide 4: Vascepa: ~70% Canadians on public plans eligible for reimbursement
Vascepa: ~70% Canadians on public plans eligible for reimbursement Catalysts now in place to drive Vascepa growth Public payer coverage ~70% publicly covered lives eligible for Vascepa reimbursement, including: Ontario, Quebec, Saskatchewan, New Brunswick and Northwest Territories Private payer cove
Slide 5: Prescription momentum growing
Vascepa: Prescription momentum growing Weekly script data since launch 1200 New Rx: 20% increase 1000 800 Total Rx: 10% increase Prescriptions 4-week period ended October 28, 2022, compared to the prior 4-week period 600 400 Ontario public listing New Rx: 12% increase 200 Quebec public listing Total
Slide 6: Growth outpacing other cardiovascular therapies
Vascepa: growth outpacing other cardiovascular therapies New Rx Total Rx 100% 120% 93% 99% 100% 80% 71% 72% Percentage growth Percentage growth 80% 74% 71% 60% 60% 40% 40% 24% 26% 24% 23% 20% 17% 14% 20% 7% 7% 6% 4% 5% 4% 0% 0% Month Quarter MAT Month Quarter MAT Vascepa PCSK9 Statins Vascepa PCSK9
Slide 7: Broadening the user base
Vascepa: Broadening the user base Total Rx by Physician Group As market access increases, General Practitioner our strategy is to leverage the Cardiologist 4x expansion in physician Endocrinologist audience to 10,000 with IM greater call frequency to Other create awareness, trial and Source: IQVIA a
Slide 8: RESPECT-EPA: shows CV benefit consistent with REDUCE-IT and JELIS
RESPECT-EPA: shows CV benefit consistent with REDUCE-IT® and JELIS 21.5 % 26.6 % Years to event Years to event 27.5 % 1.8g/day purified EPA Trial funded by the significantly associated Japanese Heart with decreased risk of Foundation events related to coronary artery disease Years to event Provided
Slide 9: Q3 2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q3 2022 Results Conference Call November 10, 2022 TSX - HLS